Tetraphase Pharmaceuticals Inc (TTPH):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Tetraphase Pharmaceuticals Inc (TTPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9813
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Tetraphase Pharmaceuticals Inc (Tetraphase) is a pharmaceutical company that discovers and develops antibiotic resistance medicines. The company’s products under clinical development include eravacycline, TP-271, and TP-6076. It develops products for the treatment of respiratory diseases caused by bacterial biothreat and antibiotic resistant public health pathogens. Tetraphase’s eravacycline is used for the treatment of multi-drug resistant (MDR) infections which include MDR gram-negative bacteria. The company offers drugs in therapeutic areas of antibiotics, oncology and inflammatory diseases. It also offers research and creation of tetracycline drugs. Tetraphase is headquartered in Watertown, Massachusetts, the US.

Tetraphase Pharmaceuticals Inc (TTPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Tetraphase Pharma Raises Funds Through Venture Financing 11
Licensing Agreements 12
Everest Medicines Enters into Licensing Agreement with Tetraphase Pharma 12
Equity Offering 13
Tetraphase Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 13
Tetraphase Pharma Raises USD65 Million in Public Offering of Shares 14
Tetraphase Pharmaceuticals Raises USD7.6 Million in Public Offering of Common Stock 16
Tetraphase Pharma Raises USD5.6 Million in Public Offering of Shares 17
Tetraphase Pharma Increase its Size of Public Offering of Shares for USD80 Million 19
Tetraphase Pharma Raises USD173 Million in Public Offering of Shares 20
Tetraphase Pharma Raises USD86.3 Million in Public Offering of Shares 22
Tetraphase Pharma Completes Underwriters’ Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$49 Million 24
Tetraphase Pharma Announces That Underwriters’ Of Its IPO Exercise Their Over-Allotment Option 26
Acquisition 28
Tetraphase Pharma May Sell Itself 28
Tetraphase Pharmaceuticals Inc – Key Competitors 30
Tetraphase Pharmaceuticals Inc – Key Employees 31
Tetraphase Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Financial Announcements 33
Aug 02, 2018: Tetraphase Pharmaceuticals reports second quarter 2018 financial results and recent highlights 33
May 03, 2018: Tetraphase Pharmaceuticals Reports First Quarter 2018 Financial Results and Recent Highlights 35
Mar 06, 2018: Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2017 Financial Results, Highlights Achievements and Key 2018 Milestones 37
Nov 02, 2017: Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements 39
Aug 02, 2017: Tetraphase Pharmaceuticals Reports Second Quarter 2017 Financial Results 41
Aug 02, 2017: Tetraphase Q2 net loss up 42
May 04, 2017: Tetraphase Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Recent Highlights 43
Mar 08, 2017: Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones 44
Corporate Communications 46
Mar 01, 2018: Tetraphase Pharmaceuticals Appoints Larry Edwards Chief Operating Officer 46
Oct 16, 2017: Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer 47
Other Significant Developments 48
Aug 27, 2018: Tetraphase Pharmaceuticals to participate at upcoming investor conferences 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tetraphase Pharma Raises Funds Through Venture Financing 11
Everest Medicines Enters into Licensing Agreement with Tetraphase Pharma 12
Tetraphase Pharma Plans to Raise up to USD150 Million in Public Offering of Shares 13
Tetraphase Pharma Raises USD65 Million in Public Offering of Shares 14
Tetraphase Pharmaceuticals Raises USD7.6 Million in Public Offering of Common Stock 16
Tetraphase Pharma Raises USD5.6 Million in Public Offering of Shares 17
Tetraphase Pharma Increase its Size of Public Offering of Shares for USD80 Million 19
Tetraphase Pharma Raises USD173 Million in Public Offering of Shares 20
Tetraphase Pharma Raises USD86.3 Million in Public Offering of Shares 22
Tetraphase Pharma Completes Underwriters’ Exercise Of Partial Over-Allotment Option Of Public Offering Of Shares For US$49 Million 24
Tetraphase Pharma Announces That Underwriters' Of Its IPO Exercise Their Over-Allotment Option 26
Tetraphase Pharma May Sell Itself 28
Tetraphase Pharmaceuticals Inc, Key Competitors 30
Tetraphase Pharmaceuticals Inc, Key Employees 31
Tetraphase Pharmaceuticals Inc, Subsidiaries 32

List of Figures
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tetraphase Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Tetraphase Pharmaceuticals Inc (TTPH):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bird Rock Bio Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Bird Rock Bio Inc (Bird Rock Bio), formerly RuiYi Inc is a clinical stage biopharmaceutical company that develops immuno-inflammatory regulators and therapeutic antiobodies. The company’s pipeline products include RYI-018, Gerilimzumab and Namacizumab. Its RYI-018 is a peripheral antagonist …
  • Nomura Holdings, Inc.:企業の戦略・SWOT・財務情報
    Nomura Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nomura Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Petro Matad Ltd (MATD):企業の財務・戦略的SWOT分析
    Summary Petro Matad Ltd (Petro Matad) is an oil and gas company that develops and operates oil and gas exploration properties. The company’s upstream oil and gas exploration asset base includes Block IV, Block XX, and Block V. Its Block XX is located in the far eastern part of Mongolia producing oil …
  • Medica Corp:医療機器:M&Aディール及び事業提携情報
    Summary Medica Corp (Medica) is a medical device company that manufactures and markets in-vitro diagnostic blood testing analyzers. The company’s products comprise clinical chemistry analyzers, electrolyte analyzers, blood gas analyzers, and hematology analyzers, and OEM ISE modules. Medica’s produc …
  • Mobidiag Ltd:企業の製品パイプライン分析
    Summary Mobidiag Ltd (Mobidiag) operates as a biotechnology company that develops and markets products for molecular diagnosis of infectious diseases and test kits. The company's products portfolio includes Novodiag, Amplidiag, and Prove-it. Its Amplidiag is a diagnostic test for high-volume screeni …
  • Schneider Electric SE (SU)-エネルギー分野:企業M&A・提携分析
    Summary Schneider Electric SE (Schneider Electric), formerly Schneider Electric SA, is an energy management and automation company that develops related technologies and solutions for electricity distribution. Its product line comprises automation and control products, building management and securi …
  • Sirtex Medical Ltd (SRX):企業の財務・戦略的SWOT分析
    Summary Sirtex Medical Ltd (Sirtex Medical) is a medical device company that develops and markets device for the treatment of liver cancer. The company’s sir-spheres microsphere is a medical device, which is used in selective internal radiation therapy for liver tumors. Its product Y-90 resin micros …
  • SK Chemicals Co Ltd (006120):企業の財務・戦略的SWOT分析
    Summary SK Chemicals Co Ltd (SK Chemicals) is a provider of chemical and pharmaceutical products. The company offers pharmaceutical drugs to treat erectile dysfunction, arthritis, peptic ulcer, gastroesophageal reflux disease (GERD), cancer and to improve blood circulation. It manufactures green che …
  • Bullet Biotechnology Inc-製薬・医療分野:企業M&A・提携分析
    Summary Bullet Biotechnology Inc (Bullet Biotechnology) focuses on the development of immunotherapies for the treatment of cancer. The company’s lead product, BB-006 is under development which is being developed to treat solid tumors. Bullet Biotechnology’s primarily interest in is immuno-oncology a …
  • Penumbra Inc (PEN):企業の財務・戦略的SWOT分析
    Penumbra Inc (PEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • SPX Corporation:企業の戦略・SWOT・財務分析
    SPX Corporation - Strategy, SWOT and Corporate Finance Report Summary SPX Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • IMPSA SA:企業の戦略的SWOT分析
    IMPSA SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Thi …
  • Xcel Energy Inc (XEL)-石油・ガス分野:企業M&A・提携分析
    Summary Xcel Energy Inc. (Xcel Energy) is a vertically-integrated energy utility that generates, procures, transmits, distributes and sells electricity; and transports, stores and distributes natural gas through its subsidiaries. The company owns and operates generation assets utilizing diverse fuel …
  • The National Gas Company of Trinidad and Tobago Ltd:企業の戦略的SWOT分析
    The National Gas Company of Trinidad and Tobago Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key compe …
  • Mednax Inc (MD):製薬・医療:M&Aディール及び事業提携情報
    Summary Mednax Inc (Mednax) is a national medical group company, which operates a network of physician service providers. The company offers a wide range of neonatal, anesthesia, maternal-fetal, pediatric physician and subspecialty services. Its network includes other pediatric subspecialists compri …
  • ThreeD Capital:企業のM&A・事業提携・投資動向
    ThreeD Capital - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's ThreeD Capital Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Shuwen Biotech Co Ltd:企業の製品パイプライン分析2018
    Summary Shuwen Biotech Co Ltd (Shuwen Biotech) is a medical equipment company. The company develops diagnostic products and services for disease prevention, diagnosis and personalized medicine. It offers in-vitro diagnostic (IVD) kits for oncology and pregnancy-related conditions. Shuwen Biotech dev …
  • China International Water & Electric Corp:企業の戦略的SWOT分析
    China International Water & Electric Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • Select Medical Holdings Corporation:企業の戦略・SWOT・財務分析
    Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Select Medical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • International Paper APPM Limited:企業の戦略・SWOT・財務情報
    International Paper APPM Limited - Strategy, SWOT and Corporate Finance Report Summary International Paper APPM Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆